Documente Academic
Documente Profesional
Documente Cultură
Al diagnóstico se ha
perdido 50% de la
masa/función de las
células b
100
la célula Beta (%)
Diagnóstico
75
Función de
IG/GAA Terapia
50 Insulínica
Diabetes
25
0
12 8 4 0 4 8 12
Insulinemia (uU/dl)
150 70
Glicemia(mg/dl)
125 50
100 30
75 10
Gly
Ile S Lys
1 Val S
Glu
Gln Cys
Gly 2 2 33
Cys Tyr Arg
5 Cys Asn Asp Arg
Phe Thr Leu
Glu 20 Thr
Ser Ile
Val S Cys Ser Leu Tyr Gln S Lys
1 Asn Pro 30
15 Thr
Gln S 10 Tyr Pro
His Phe Lys
Leu S Phe
Cys Gly 25
5 Gly
Ser
Glu
Arg 1
His Val CysGly
Leu Val
Glu Ala LeuTyr Leu 20
10
15
Rápida : Regular
Intermedias : NPH
Lenta
Ultra lenta
Prolongadas :
Plasma Insulin
Glargina
0 4 8 12 16 20 24
Insulina glargina :
una basal casi perfecta
Insulina Detemir
Tipos de insulinas ( premezclas )
NovoMix 30 ( HumalogMix25 ) :
mezcla basal / prandial
35 Fase
Postprandial
25
15
5 Fase Interprandial
0
4 8 12 16 20 24
Inyección Tiempo (hora)
77%
alcanzaron la
meta de la ADA de A1C
100
TID
Patients % A1C <7%
80
60 BID
40
20 QD
0
50 10
40 8
30 6
20 4
10 2
0 0
0 3 6 9 12 15 0 3 6 9 12 15
Convencional Years from randomisation
Insulina
Clorpropamida
Glibenclamida
1er paso : educación
Métodos de colocación de la insulina
2º paso : iniciando la Insulina
( Insulina basal )
• Continuar agentes orales misma dosis ( eventualmente
ajustar sulfonilures ). Suspender glitazonas.
• Objetivo de Tratamiento :
Titration at a
once-daily dose
3 units
3
FPG target range
0 0
Maintain
dose
Decrease
FPG <90 mg/dl
dose 3
3 units
H.Yki-Järvinen, A. Dressler, M. Ziemen y el Grupo de Estudio HOE 901/3002; Universidad de Helsinki, Helsinki, Finlandia.
1CHR Corbeil, 2 Aventis Francia, 3 Hôpital George Pompidou, París, 4CHR Grenoble, 5CHU Pitié-Salpétrière, Lyon, Francia.
Cambio en el peso corporal a las
20 semanas : Detemir pm vs. NPH pm
p = 0.005
Cambio en el peso
(kg)
0.7 1.6
Det pm NPH pm
Consideraciones sobre el esquema
0 1 2 3
Years
- 0.5
* Mean baseline HbA1c (%)
60
40 32.3
26.4
18.4
20
0
BiF start Prandial start Basal start
group group group
Year 3
*
10
Median events per patient
*
8
8 ** Minor hypoglycaemia
did occur in the first
**
# year with detemir
6 # 5.7
per year
*p=0.002 and p<0.001 vs. biasp 30 and detemir respectively at year one
**p<0.001 vs. biasp 30 and detemir at year three
#p=0.01 vs. detemir at year one
##p<0.001 vs. detemir at year three
Holman RR et al., New England Journal of Medicine, 2007; 357:1716-30
Holman et al. New England Journal of Medicine 2009; 361:1736-47
4T : peso corporal
Year 1
10
Weight change from baseline
## Year 3
#
8 **
* † 6.4
5.7 5.7
6 4.7
3.6
(kg)
4
1.9
2
0
BiF start Prandial start Basal start
group group group
†p=0.005 vs. aspart at year one; *p<0.001 vs. detemir at year one
#p<0.001 vs. detemir at year one
**p=0.005 vs. detemir at year three; ## p<0.001 vs. detemir at year three
– Bifásica 7.1%
– Prandial 6.8%
– Basal 6.9%
• HbA1c en target :
≤6.5% ≤7.0%
– Bifásica 31.9% 49.4%
– Prandial 44.8% 67.4%
– Basal 43.2% 63.2%